(Press-News.org) Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long-term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy (DAPT) following the insertion of a coronary stent. After two years of follow-up, chronic maintenance therapy with clopidogrel resulted in a 30% reduction in deaths, heart attacks, strokes or major bleeding events, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
"These data confirm our working hypothesis that long-term maintenance antiplatelet monotherapy with clopidogrel produces better outcomes than aspirin in patients who are adverse event-free at one year after coronary stenting," said Hyo-Soo Kim, MD, PhD, professor of internal medicine at Seoul National University Hospital in South Korea and lead author of the study.
The trial met its primary endpoint, a composite of death from any cause, heart attack, stroke or a major bleeding event within two years of study entry, which occurred in 5.7% of patients assigned to clopidogrel and 7.7% of those assigned to aspirin.
Ischemic heart disease is an umbrella term for problems caused by insufficient blood flow to the heart, such as heart attacks and unstable angina. Stenting, also known as coronary angioplasty or percutaneous coronary intervention, is a minimally invasive procedure in which a flexible tube (catheter) is threaded through an artery under local anesthesia. At the site of an arterial blockage, a tiny balloon at the tip of the catheter is inflated to unblock the artery, and a stent--a tiny mesh tube coated with medication--is inserted to prop the coronary artery open and restore blood flow to the heart.
Blood cells known as platelets help the blood to clot, and both clopidogrel and aspirin stop platelets from clotting. Current treatment guidelines recommend a DAPT regimen of two antiplatelet drugs for six to 12 months after the insertion of a coronary stent to prevent blood clots.
"However, the optimal single antiplatelet agent for long-term maintenance therapy beyond the duration of DAPT has been unclear," Kim said. He added that in clinical practice, physicians may maintain patients on DAPT for as long as 18 months, depending on the patients' level of risk for clotting.
This trial, known as HOST-EXAM (EXtended Antiplatelet Monotherapy), enrolled 5,436 patients who had received a coronary stent. Patients' average age was 63 years; 75% were men, 34% had diabetes and 13% had chronic kidney disease. After completing between six and 18 months of DAPT without experiencing any adverse events, patients were randomly assigned to receive single-agent maintenance therapy with either clopidogrel or aspirin.
In addition to the primary endpoint, researchers also separated out blood-clotting events (death, heart attack, hospital readmission due to acute coronary syndrome, or a blood clot in the stent) from all bleeding events and analyzed them as secondary endpoints. They found that blood-clotting events occurred in 3.8% of the patients who took clopidogrel compared with 5.6% of those who took aspirin; bleeding events were seen in 2.3% of patients in the clopidogrel group versus 3.3% of those in the aspirin group. All of the differences between the groups were statistically significant.
"These results confirm that clopidogrel is superior to aspirin at reducing the incidence of blood-clotting events," Kim said. "What is interesting is that clopidogrel also performed better than aspirin at reducing bleeding events. Such findings that one antiplatelet agent is better than the other in reducing both clotting and bleeding events have been observed in other studies comparing different antiplatelet regimens, suggesting that thrombotic and bleeding events are tightly associated with each other. For example, when patients experience bleeding, they stop the antiplatelet agents leading [them to experience] thrombotic events."
Kim said that the results apply only to patients who had completed between six and 18 months of DAPT without any adverse events.
"It may be difficult to directly extrapolate our results to patients who received DAPT for a shorter period, such as one or three months," he said. "However, our results may be useful in helping physicians to select antiplatelet monotherapy for patients who are in the chronic stable phase after coronary stenting."
The two years of patient follow-up in the HOST-EXAM trial is longer than that of many previous trials comparing antiplatelet drug regimens in patients who have received a coronary stent, Kim said. He and his colleagues plan to continue their follow-up for a total of five years to gain further insights into the long-term benefits and trade-offs of clopidogrel compared with aspirin. Because the daily cost of clopidogrel is higher than that of aspirin, Kim said, he and his team are also planning a follow-up study that will examine the cost-effectiveness of the two medications.
Another limitation is that the trial was not blinded, meaning that both patients and their doctors knew which drug patients were receiving. Also, the total number of reported adverse events in both groups was lower than the investigators had expected when they designed the trial, which suggests that adverse events could have been under-reported. However, Kim said he believes the main reason for the lower-than-expected rate of adverse events was not under-reporting but the quality of care that evolved over the seven-year study period.
INFORMATION:
The study was funded by the South Korean Ministry of Health and Welfare and by four Korea-based pharmaceutical companies.
This study was simultaneously published online in The Lancet at the time of presentation.
Kim will be available to the media in a virtual press conference on Sunday, May 16, at 12:15 p.m. ET / 16:15 UTC.
Kim will present the study, "Aspirin Vs. Clopidogrel During Chronic Maintenance Monotherapy After Percutaneous Coronary Intervention: The Host Exam Randomized Controlled Trial," on Sunday, May 16, at 10:45 a.m. ET / 14:45 UTC, virtually.
ACC.21 will take place May 15-17 virtually, bringing together cardiologists and cardiovascular specialists from around the world to share the newest discoveries in treatment and prevention. Follow @ACCinTouch, @ACCMediaCenter and #ACC21 for the latest news from the meeting.
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its 54,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit ACC.org.
Media Contacts
Nicole Napoli
202-669-1465
nnapoli@acc.org
Thy-Ann Nguyen
703-479-3642
thyann.nguyen@curastrategies.com
Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session. In fact, a subset of patients receiving this more sensitive and frequent blood testing protocol were more likely to have a heart attack or to die during the one-year follow-up period compared with patients whose treatment was informed by the results of conventional blood testing procedures.
Troponins are proteins found in ...
Among patients who had a cardiac stent inserted after a heart attack, switching to less-potent dual antiplatelet therapy (DAPT) after 30 days was safer and more effective in preventing adverse events a year later than continuing on a high-potency DAPT regimen, according to data presented at the American College of Cardiology's 70th Annual Scientific Session.
"We have shown that, in patients who have had a heart attack and who've been treated with newer-generation stents and guideline-recommended medical therapy, de-escalation of DAPT by switching from ticagrelor to clopidogrel is completely safe and more effective than continuing to treat patients with ticagrelor," said Kiyuk Chang, MD, professor of Cardiology, Division of Internal Medicine at the Catholic University of ...
People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented at the American College of Cardiology's 70th Annual Scientific Session.
Severe hypertriglyceridemia is a rare disorder that causes extremely high levels of triglycerides, an accumulation of fat in the blood that can lead to heart, liver and pancreatic disease. People with severe hypertriglyceridemia commonly have triglyceride levels of 1,000 mg/dL ...
Patients at high risk for cardiovascular events who had the highest levels of eicosapentaenoic acid (EPA) in their blood one year after taking daily omega-3 carboxylic acid, a prescription-grade fish oil, had similar rates of major cardiovascular events as people taking a corn oil placebo, according to a secondary analysis of the STRENGTH trial presented at the American College of Cardiology's 70th Annual Scientific Session. Researchers also found no increase in cardiovascular events among patients with the highest levels of docosahexaenoic acid (DHA) compared to placebo.
The impetus for this post-hoc analysis was to further examine the strikingly divergent results between STRENGTH and REDUCE-IT, another large, randomized clinical trial that used a ...
Dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, did not significantly reduce the risk of organ failure or death or improve recovery in patients hospitalized with COVID-19 who are at high risk of developing serious complications compared to placebo, according to data presented at the American College of Cardiology's 70th Annual Scientific Session. The researchers, while acknowledging the results were not statistically significant, said they were encouraged by the lower numbers of organ failure and deaths observed in patients treated with dapagliflozin and by favorable safety ...
Older patients hospitalized with acute heart failure who participated in a novel 12-week physical rehabilitation (rehab) program tailored to address their specific physical impairments had significant gains not only in physical functioning but also quality of life and depression compared with those receiving usual care, regardless of their heart's ejection fraction, according to a new study presented at the American College of Cardiology's 70th Annual Scientific Session. Participation in the program, however, did not significantly reduce rehospitalizations during the six-month follow up.
Heart failure, which ...
Taking medications to protect the heart from damage associated with adjuvant breast cancer therapy--medications that are administered in addition to surgery to remove a tumor--did not significantly improve markers of heart health two years after breast cancer treatment, according to a study presented at the American College of Cardiology's 70th Annual Scientific Session.
The researchers reported no significant differences between patients who took an angiotensin receptor blocker (candesartan cilexetil) or a beta-blocker (metoprolol succinate) compared with placebos in terms of left ventricular ejection fraction (LVEF), a measure of the heart's ability to effectively pump ...
Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg. The findings, presented at the American College of Cardiology's 70th Annual Scientific Session, expand on earlier data and underscore the broad absolute benefits of this strategy in this high-risk patient population, researchers said.
"To our knowledge, this is the first time that the addition of low-dose rivaroxaban to aspirin has been clearly shown to reduce ...
In patients who had a coronary stent inserted after experiencing the most severe type of heart attack, the use of a technique that measures blood flow and pressure through a partially blocked artery to determine if a second stenting procedure is needed did not improve outcomes and was more costly than using angiography, or a heart X-ray, alone to guide the procedure, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.
"The strategy of using fractional flow reserve (FFR) to guide the stenting procedure is not superior to the standard technique of using angiography to treat additional partially blocked arteries," said Etienne Puymirat, MD, professor of cardiology at the University of Paris, director of intensive care at the Georges ...
HOUSTON - (May 17, 2021) - In an important step toward the clinical application of synthetic biology, Rice University researchers have engineered a bacterium with the necessary capabilities for diagnosing a human disease.
The engineered strain of the gut bacteria E. coli senses pH and glows when it encounters acidosis, an acidic condition that often occurs during flareups of inflammatory bowel diseases like colitis, ileitis and Crohn's disease.
Researchers at the University of Colorado (CU) School of Medicine used the Rice-created organism in a mouse model of Crohn's disease to show acidosis activates a signature set of genes. The corresponding ...
